GlassScriptPhysician profile
Stephen H Yandel
NPI 1952366619
$7,277.14
in general payments reported to CMS, 2019-2025
60 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $1,000 · 2021: $2,790 · 2022: $1,857 · 2023: $162 · 2024: $747 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,301.34 | 2019-2025 | |
| Pfizer INC. | $728.81 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $612.51 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $543.20 | 2020-2024 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $536.00 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $359.68 | 2021-2023 | Tukysa |
| Genzyme Corporation | $291.86 | 2019-2022 | |
| Janssen Biotech, INC. | $189.50 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $189.40 | 2020-2024 | Opdivo |
| Beigene USA, INC. | $150.02 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $148.92 | 2021-2024 | Zepzelca |
| Abbvie INC. | $145.88 | 2021-2024 | |
| Astellas Pharma US INC | $124.38 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.98 | 2021-2022 | |
| Celgene Corporation | $114.27 | 2020-2024 | Reblozyl |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Yandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.